Contact

Are you a client? You should contact your private banker. 
You are not a client but would like to have more information about Societe Generale Private Banking ? Please fill in the form below.

Local contacts

France : +33 (0) 1 42 14 20 00 (9am - 5pm)
Luxembourg : +352 47 93 11 1 (8:30am - 6pm)
Monaco : +377 97 97 58 00 (9/12am - 2/5pm)
Switzerland : Geneva +41 22 819 02 02
& Zurich +41 44 218 56 11 (8:30am - 5:30pm)

You would like to contact about the protection of your personal data ?

Please contact the Data Protection Officer of Societe Generale Private Banking France by sending an email to the following address : protectiondesdonnees@societegenerale.fr.

Please contact Bieneke Russon, the Data Protection Officer of Societe Generale Bank & Trust Luxembourg by phone : +352-47.93.93.11.5046 or by sending an email to the following address : lux.dpooffice@socgen.com.

Please contact Roman Janecek, the Data Protection Officer of Societe Generale Private Banking Monaco by sending an email to the following address : MONPrivmonaco-DPO@socgen.com.

Please contact Omar Otmani, the Data Protection Officer of Societe Generale Private Banking Switzerland by sending an email to the following address : sgpb-gdpr.ch@socgen.com.

You need to make a claim ?

 Any claim addressed to Societe Generale Private Banking France should be sent by e-mail to the following address : FR-SGPB-Relations-Clients@socgen.com or by mail to : 

Société Générale Private Banking France
Direction Commerciale
29 boulevard Haussmann CS 614
75421 Paris Cedex 9

The Bank will acknowledge your request within 10 days after receipt and provide a response to your claim within 60 days of receipt. If your request requires additional processing time (e.g. if it involves complex researches…), the Bank will inform you by mail. 

In the event that the response you receive does not meet your expectations, we suggest to contact : 

 

The Societe Generale Group’s Ombudsman

The Societe Generale Group’s Ombudsman can be contacted by the following website : mediateur.societegenerale.fr  or by mail :

Le Médiateur auprès de Société Générale
17 Cours Valmy 
92987 PARIS LA DEFENSE CEDEX 7
France

In reviewing any matter, the Ombudsman undertakes the consideration of both the client’s and the bank’s point of view, evaluates arguments from each of the parties and makes a decision in all fairness.

The Group’s Ombudsman will respond to you directly within two months of receipt of the written submissions of the parties relating to the claim.

 

The Ombudsman of the AMF

The Ombudsman of the Autorité des Marchés Financiers (AMF) can be contacted at the following address :

Médiateur de l'AMF, Autorité des Marchés Financier
17 place de la Bourse
75082 PARIS CEDEX 02
FRANCE


The Insurance Ombudsman

Please contact the Insurance Ombudsman : contact details must be mentioned in your insurance contract.

To ensure that your requests are handled effectively, any claim addressed to Societe Generale Bank & Trust should be sent to:

Private banking Claims department
11, Avenue Emile Reuter
L-2420 Luxembourg

The Bank will acknowledge your request within 10 days and provide a response to your claim within 30 days of receipt. If your request requires additional processing time (e.g. if it involves complex research), the Bank will inform you of this situation within the same 30-day timeframe.

In the event that the response you receive does not meet your expectations, we suggest the following :

Initially, you may wish to contact the SGBT Division responsible for handling claims, at the following address:

Corporate Secretariat of Societe Generale Bank & Trust
11, Avenue Emile Reuter
L-2420 Luxembourg

If the response from the Division responsible for claims does not resolve the claim, you may wish to contact Societe Generale Bank & Trust's supervisory authority, the Commission de Surveillance du Secteur Financier (Financial Sector Supervisory Commission) :

By mail: 283, Route d’Arlon L-1150 Luxembourg
By e-mail:direction@cssf.lu

 Any claim addressed to Societe Generale Private Banking Monaco should be sent by e-mail to the following address : reclamation.privmonaco@socgen.com or by mail to our dedicated department : 

Societe Generale Private Banking Monaco
Middle Office – Service Réclamation 
13,15 Boulevard des Moulins 
98000 Monaco

The Bank will acknowledge your request within 2 days after receipt and provide a response to your claim within 10 days of receipt. If your request requires additional processing time (e.g. if it involves complex researches…), the Bank will inform you of this situation within the same 30-day timeframe. 

In the event that the response you receive does not meet your expectations, we suggest to contact the Societe Generale Private Banking Direction that handles the claims by mail at the following address : 

Secrétariat Général de Societe Generale Private Banking Monaco 
13,15 Boulevard des Moulins 
98000 Monaco

Any claim addressed to the Bank can be sent by email to: sgpb-reclamations.ch@socgen.com
Clients may also contact the Swiss Banking Ombudsman : www.bankingombudsman.ch

Interview with Michel Feraud, President of Provepharm

By giving a second therapeutic life to forgotten molecules, Provepharm Life Solutions is building a global pharmaceutical group. Its strategy ? Accelerated innovation and making treatments available to as many people as possible.

A researcher who wants to find himself

Michel Feraud was a young student of organic chemistry at the Université Saint-Jérôme in Marseilles when it clicked: “I considered chemistry to be like Lego® where molecules could be transformed into medicines to cure.” In 1997, armed with their doctorates, Michel Feraud and his childhood friend, Christophe Baralotto, decided to start their company — without capital — which would in time become Provepharm Life Solutions. “Even if we had no idea what we were going to do, we knew exactly where we were going to do it, that is, all over the world.”

 

Controlled risk-taking

The company began by offering its services to other laboratories such as L'Oréal, Johnson & Johnson and even Aventis. At the same time, it looked to investors, while ensuring that its shareholders remained independent. “We financed, for example, through convertible bonds*, contrary to the practices of the time. We therefore managed to preserve the majority of our capital." In 2018, the Tethys fund of the Bettencourt family and ArchiMed — the first independent European funds dedicated to this sector — also contributed to the capital. And Michel Feraud and Christophe Baralotto still hold 67% of the shares.

(*) Type of bonds offering a right of conversion into shares.

Reinventing methylene blue

In 2007, Provepharm Life Solutions reinvented a decidedly vintage remedy, methylene blue. The molecule, discovered in 1876, has many antiseptic and antioxidant qualities.
But, because it contains some potentially toxic heavy metals, its therapeutic use has been progressively phased out and banned. By patenting a process that eliminates these heavy metals, the company re-created methylene blue under the name Provayblue®, and with it, developed a new antidote against severe blood poisoning. In country after country, the national drug agencies gave marketing authorisation for this regenerated molecule. “It all started with France in 2010, and today we have a presence in nearly 35 countries.” The most recent marketing authorisations were obtained in the United States.

“In 2016, we secured a sevenyear agreement for the exclusive commercialisation of Provayblue® by obtaining an orphan drug designation. As a responsible company, this agreement requires us to ensure that products are always available throughout the United States — which is normal. For this purpose, we have a strategic stock of 200,000 units in the United States. That represents a six months’ treatment supply, proof that we are 100% patient oriented. It is unthinkable that someone has to do without their therapy because a laboratory has not been able to manage their supply chain or, much worse, has made unreasonable profits through financial arbitrage.”

 

Innovation at the heart of company philosophy

If Provepharm Life Solutions' R&D teams are doing so well, it's probably because shareholders and management give them time to work their magic. “At Provepharm Life Solutions, we have a real desire to encourage the entrepreneur within all our employees. In a world in search of purpose, we want to give meaning to intelligence and, above all, we want to avoid sheep-like behaviour. I am convinced that companies need to carry a core message with them. Ours is that there is a third way between biotechs and generic specialists, i.e. reinventing molecules with prior therapeutic virtues, making them compatible with the very strict specifications of modern health agencies.”

€42.5 million to accelerate growth

The creation of a new 3,000 m2 production unit in Marseilles, an investment of €9 million and the establishment of a new subsidiary in the United States are all signs that underline the fast-paced development of Provepharm Life Solutions.
Its turnover increased by 27% in one year to €38 million by the end of 2018. To support its new projects, the company has just obtained a syndicated credit* of €42.5 million.

 

From research against malaria to committed social responsibility

Among other ongoing research, Provepharm Life Solutions is working on a treatment for malaria, that is already supported by the US Army. Size is certainly an issue.
According to WHO, this disease killed 429,000 people in 2015, with nearly 212 million recorded cases worldwide. Their strategy? No Gain, No Loss. “We are not driven by earnings, but we do not want to lose money either.” To speed up its R&D, the company therefore relies on nurturing the talents of their employees, an international cast hailing from over ten different countries, worldwide. At the same time, diversity is particularly close to their hearts. For example, women make up the majority of the workforce and three women sit on the board of directors. To conclude this interview, Michel Feraud also wished to mention one of the key factors of his success.
“Regardless of a person's profession or their sector of activity, I think it's important to dare to use common sense. This third way is full of opportunities for both business and people. And above all, it creates societal value that can be shared by all.” In this area, Michel certainly knows what he is talking about.

(*) Loan granted by several banks to the same company.